27257822|t|Comparative Epidemiologic Characteristics of Pertussis in 10 Central and Eastern European Countries, 2000-2013
27257822|a|We undertook an epidemiological survey of the annual incidence of pertussis reported from 2000 to 2013 in ten Central and Eastern European countries to ascertain whether increased pertussis reports in some countries share common underlying drivers or whether there are specific features in each country. The annual incidence of pertussis in the participating countries was obtained from relevant government institutions and/or national surveillance systems. We reviewed the changes in the pertussis incidence rates in each country to explore differences and/or similarities between countries in relation to pertussis surveillance; case definitions for detection and confirmation of pertussis; incidence and number of cases of pertussis by year, overall and by age group; population by year, overall and by age group; pertussis immunization schedule and coverage, and switch from whole-cell pertussis vaccines (wP) to acellular pertussis vaccines (aP). There was heterogeneity in the reported annual incidence rates and trends observed across countries. Reported pertussis incidence rates varied considerably, ranging from 0.01 to 96 per 100,000 population, with the highest rates generally reported in Estonia and the lowest in Hungary and Serbia. The greatest burden appears for the most part in infants (<1 year) in Bulgaria, Hungary, Latvia, Romania, and Serbia, but not in the other participating countries where the burden may have shifted to older children, though surveillance of adults may be inappropriate. There was no consistent pattern associated with the switch from wP to aP vaccines on reported pertussis incidence rates. The heterogeneity in reported data may be related to a number of factors including surveillance system characteristics or capabilities, different case definitions, type of pertussis confirmation tests used, public awareness of the disease, as well as real differences in the magnitude of the disease, or a combination of these factors. Our study highlights the need to standardize pertussis detection and confirmation in surveillance programs across Europe, complemented with carefully-designed seroprevalence studies using the same protocols and methodologies.
27257822	45	54	Pertussis	T038	UMLS:C0043167
27257822	61	68	Central	T082	UMLS:C0454714
27257822	73	99	Eastern European Countries	T082	UMLS:C0015177
27257822	127	149	epidemiological survey	T062	UMLS:C0376688
27257822	177	186	pertussis	T038	UMLS:C0043167
27257822	187	195	reported	T058	UMLS:C0700287
27257822	221	228	Central	T082	UMLS:C0454714
27257822	233	259	Eastern European countries	T082	UMLS:C0015177
27257822	291	300	pertussis	T038	UMLS:C0043167
27257822	301	308	reports	T170	UMLS:C0025102
27257822	317	326	countries	T082	UMLS:C0454664
27257822	406	413	country	T082	UMLS:C0454664
27257822	439	448	pertussis	T038	UMLS:C0043167
27257822	470	479	countries	T082	UMLS:C0454664
27257822	507	530	government institutions	T092	UMLS:C2607850
27257822	538	567	national surveillance systems	T092	UMLS:C1708333
27257822	600	609	pertussis	T038	UMLS:C0043167
27257822	634	641	country	T082	UMLS:C0454664
27257822	693	702	countries	T082	UMLS:C0454664
27257822	718	727	pertussis	T038	UMLS:C0043167
27257822	763	772	detection	T033	UMLS:C0442726
27257822	793	802	pertussis	T038	UMLS:C0043167
27257822	837	846	pertussis	T038	UMLS:C0043167
27257822	882	892	population	T098	UMLS:C1257890
27257822	928	937	pertussis	T038	UMLS:C0043167
27257822	938	959	immunization schedule	T058	UMLS:C0020972
27257822	990	1019	whole-cell pertussis vaccines	T103	UMLS:C0031237
27257822	1021	1023	wP	T103	UMLS:C0031237
27257822	1028	1056	acellular pertussis vaccines	T103	UMLS:C0982332
27257822	1058	1060	aP	T103	UMLS:C0982332
27257822	1094	1102	reported	T058	UMLS:C0700287
27257822	1153	1162	countries	T082	UMLS:C0454664
27257822	1164	1172	Reported	T058	UMLS:C0700287
27257822	1173	1182	pertussis	T038	UMLS:C0043167
27257822	1256	1266	population	T098	UMLS:C1257890
27257822	1301	1309	reported	T058	UMLS:C0700287
27257822	1313	1320	Estonia	T082	UMLS:C0014908
27257822	1339	1346	Hungary	T082	UMLS:C0020174
27257822	1351	1357	Serbia	T082	UMLS:C0036708
27257822	1429	1437	Bulgaria	T082	UMLS:C0006368
27257822	1439	1446	Hungary	T082	UMLS:C0020174
27257822	1448	1454	Latvia	T082	UMLS:C0023128
27257822	1456	1463	Romania	T082	UMLS:C0035826
27257822	1469	1475	Serbia	T082	UMLS:C0036708
27257822	1512	1521	countries	T082	UMLS:C0454664
27257822	1691	1693	wP	T103	UMLS:C0031237
27257822	1697	1708	aP vaccines	T103	UMLS:C0982332
27257822	1712	1720	reported	T058	UMLS:C0700287
27257822	1721	1730	pertussis	T038	UMLS:C0043167
27257822	1769	1777	reported	T058	UMLS:C0700287
27257822	1920	1929	pertussis	T038	UMLS:C0043167
27257822	1930	1948	confirmation tests	T058	UMLS:C0022885
27257822	1955	1961	public	T092	UMLS:C0678367
27257822	1979	1986	disease	T038	UMLS:C0043167
27257822	2040	2047	disease	T038	UMLS:C0043167
27257822	2129	2138	pertussis	T038	UMLS:C0043167
27257822	2139	2148	detection	T033	UMLS:C0442726
27257822	2169	2190	surveillance programs	T062	UMLS:C1515095
27257822	2198	2204	Europe	T082	UMLS:C0015176
27257822	2243	2265	seroprevalence studies	T062	UMLS:C0600367
27257822	2281	2290	protocols	T170	UMLS:C0442711
27257822	2295	2308	methodologies	T062	UMLS:C0086912